LEXX (Lexaria Bioscience) E10: $-1.37 (As of Feb. 2026)


LEXX Lexaria Bioscience Corp LEXX
28 GF Score
Price $0.54
GF Value $0.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lexaria Bioscience E10?

Lexaria Bioscience LEXX -3.61% 28 E10 is $-1.37 as of Feb. 2026. GuruFocus rates LEXX with a GF Score™ of 28/100 and a GF Value™ of $0.75 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Lexaria Bioscience's adjusted earnings per share data for the three months ended in Feb. 2026 was $-0.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.37 for the trailing ten years ended in Feb. 2026.

During the past 3 years, the average E10 Growth Rate was 2.00% per year. During the past 5 years, the average E10 Growth Rate was -0.70% per year. During the past 10 years, the average E10 Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Lexaria Bioscience was 18.10% per year. The lowest was -4.10% per year. And the median was 0.75% per year.

As of today (2026-06-25), Lexaria Bioscience's current stock price is $0.542. Lexaria Bioscience's E10 for the quarter that ended in Feb. 2026 was $-1.37. Lexaria Bioscience's Shiller PE Ratio of today is .


Lexaria Bioscience  (NAS:LEXX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Lexaria Bioscience E10 Related Terms


Lexaria Bioscience E10 Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience E10 Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.39 -1.52 -1.59 -1.45 -1.43

Lexaria Bioscience Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.43 -1.42 -1.43 -1.40 -1.37

LEXX vs MBRX, ICU, INTI: E10 Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Shiller PE Ratio falls into.


LEXX
28GF Score
Lexaria Bioscience Corp LEXX
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lexaria Bioscience's adjusted earnings per share data for the three months ended in Feb. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Feb. 2026 (Change)*Current CPI (Feb. 2026)
=-0.06/131.0772*131.0772
=-0.060

Current CPI (Feb. 2026) = 131.0772.

Lexaria Bioscience Quarterly Data

per share eps CPI Adj_EPS
201605 -0.300 101.765 -0.386
201608 -0.300 101.686 -0.387
201611 -0.300 101.607 -0.387
201702 -0.300 102.476 -0.384
201705 -0.300 103.108 -0.381
201708 -0.300 103.108 -0.381
201711 -0.300 103.740 -0.379
201802 -0.600 104.688 -0.751
201805 -1.500 105.399 -1.865
201808 -0.300 106.031 -0.371
201811 -0.300 105.478 -0.373
201902 -0.300 106.268 -0.370
201905 -0.300 107.927 -0.364
201908 -0.300 108.085 -0.364
201911 -0.330 107.769 -0.401
202002 -0.380 108.559 -0.459
202005 -0.500 107.532 -0.609
202008 -0.240 108.243 -0.291
202011 -0.240 108.796 -0.289
202102 0.090 109.745 0.107
202105 -0.500 111.404 -0.588
202108 -0.240 112.668 -0.279
202111 -0.350 113.932 -0.403
202202 -0.250 115.986 -0.283
202205 -0.410 120.016 -0.448
202208 -0.240 120.569 -0.261
202211 -0.300 121.675 -0.323
202302 -0.220 122.070 -0.236
202305 -0.370 124.045 -0.391
202308 -0.120 125.389 -0.125
202311 -0.130 125.468 -0.136
202402 -0.060 125.468 -0.063
202405 -0.130 127.601 -0.134
202408 -0.150 127.838 -0.154
202411 -0.160 127.838 -0.164
202502 -0.150 128.786 -0.153
202505 -0.210 129.813 -0.212
202508 -0.130 130.208 -0.131
202511 -0.070 130.682 -0.070
202602 -0.060 131.077 -0.060

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.37 mean?
Lexaria Bioscience (LEXX) has a E10 of $-1.37 as of Feb. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's E10 too high?
Lexaria Bioscience's current E10 is $-1.37. Overall, Lexaria Bioscience has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's E10 compare to MBRX and ICU?
Lexaria Bioscience's E10 of $-1.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current E10 is $-1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.75, compared to a current price of $0.54 — trading 27.7% below its estimated fair value. The current E10 is $-1.37. Lexaria Bioscience's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current E10 is $-1.37 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued. The current stock price of $0.54 is trading 27.7% below its estimated GF Value™ of $0.75. GuruFocus considers Lexaria Bioscience to be Modestly Undervalued.

Key valuation signals for LEXX:

  • E10: $-1.37
  • GF Value™: $0.75 vs. price of $0.54 (27.7% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
28GF Score

Get the complete analysis for LEXX

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.75
GF Value